United States

FFO (TTM)

FFO/share (TTM)

FFO/share Guidance

FFO (Quarter)

FFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/FFO

Size (ft²)

Total Portfolio Occupancy

Retail is evolving, and we are here to lead. We intend to profit from the dislocation in retail real estate by investing in and redeveloping mispriced and misunderstood assets. SITE Centers seeks to produce compelling, sustainable results for stakeholders through creative and active management of retail real estate.

SITE Centers

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

As a long-term debt issuer, SITC is classified as investment grade

Period: 2021 Q4

Years since IPO: 15/15,
FFO Growth: 3/15,
FFO/share Growth: 3/20,
Dividend Growth: 5/20,
Payout Ratio: 15/15,
Debt: 13/15
            

Period: 2022 Q1

Years since IPO: 15/15,
FFO Growth: 10/15,
FFO/share Growth: 3/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 13/15
            

Period: 2022 Q2

Years since IPO: 15/15,
FFO Growth: 10/15,
FFO/share Growth: 3/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 13/15
            

Period: 2022 Q3

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 3/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 13/15
            

Period: 2022 Q4

Years since IPO: 15/15,
FFO Growth: 13/15,
FFO/share Growth: 3/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q1

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 13/15
            

Period: 2023 Q2

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 13/15
            

Period: 2023 Q3

Years since IPO: 15/15,
FFO Growth: 15/15,
FFO/share Growth: 20/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 13/15
            

Period: 2023 Q4

Years since IPO: 15/15,
FFO Growth: 13/15,
FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q1

Years since IPO: 15/15,
FFO Growth: 10/15,
FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q2

Years since IPO: 15/15,
FFO Growth: 10/15,
FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q3

Years since IPO: 15/15,
FFO Growth: 10/15,
FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's FFO

FFO Growth

Assessment of recent increases in FFO per share, indicating profitability

FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

This CEO Interview is with David Lukes, CEO of SITE Centers. SITE Centers is an owner and operator of retail real estate whose portfolio consists of open-air properties in the most convenient locations of the wealthiest suburbs in the U.S. 

CEO Interview - David Lukes, CEO of SITE Centers

BEACHWOOD, Ohio--(BUSINESS WIRE)--SITE Centers Announces Tax Estimate for Curbline Properties Distribution.

SITE Centers Announces Tax Estimate for Curbline Properties Distribution

Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safety Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell response, with good overall safety

HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker

Two oral presentations and multiple posters on clinical and preclinical-stage candidates to be presented at SITC, demonstrating the strength of Immatics' TCR-T PRAME franchise to target solid cancers

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Data continues positive trend as additional patients are enrolled in 3 cohorts Vaccine was safe and well tolerated by participants in all 3 cohorts Protocol defined immune responses were exhibited in over 70% of patients A Phase 2 study evaluating the vaccine in the neoadjuvant setting is planned to commence in 2025 SAN JOSE, Calif. , Nov. 8, 2024 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced a presentation of new, updated positive data from the Phase 1 clinical trial of its breast cancer vaccine (NCT04674306) at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, being held in Houston, Texas.

Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

BOSTON, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced its poster presentation entitled “Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody” at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting, from November 6-10, 2024 in Houston, TX.

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” BiSKIT (Bifunctional SuperKine for ImmunoTherapy), engineered to deliver an anti-PD1-IL-2 Superkine (anti-PD1-IL-2 SK ) to the tumor microenvironment (TME), where it is conditionally activated by tumor-associated proteases

Medicenna Presents Preclinical Data from its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today is pleased to report preclinical data showing strong anti-cancer activity of its next generation, personalized, off-the-shelf, cell-based breast and prostate cancer immunotherapies, Bria-BRES+™ and Bria-PROS+™, respectively, during a poster session at the 2024 Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, held November 6-10, 2024, in Houston, TX.

BriaCell Showcases Robust Anti-Cancer Activity of Personalized Off-the-Shelf Immunotherapy Pipeline at the 2024 SITC Conference

BEACHWOOD, OHIO--(BUSINESS WIRE)--SITE CENTERS ANNOUNCES TAX ESTIMATE FOR CURBLINE PROPERTIES DISTRIBUTION.

SITE CENTERS ANNOUNCES TAX ESTIMATE FOR CURBLINE PROPERTIES DISTRIBUTION

PHASE 2 TRIAL EVALUATING ESEBA-VEC/PEMBROLIZUMAB COMBINATION RESULTED IN A 52% ORR IN PD-L1 CPS>20 PATIENTS AND ENCOURAGING PFS AND OS DATA, SUPPORTED BY HIGHLY DURABLE AND TUMOR-SPECIFIC T CELL RESPONSE, WITH GOOD OVERALL SAFETY PHASE 2 TRIAL EVALUATING ESEBA-VEC/PEMBROLIZUMAB COMBINATION RESULTED IN A 52% ORR IN PD-L1 CPS>20 PATIENTS AND ENCOURAGING PFS AND OS DATA, SUPPORTED BY HIGHLY DURABLE AND TUMOR-SPECIFIC T CELL RESPONSE, WITH GOOD OVERALL SAFETY

HOOKIPA PHARMA'S ESEBA-VEC HIGHLIGHTED IN SITC LATE-BREAKER

TWO ORAL PRESENTATIONS AND MULTIPLE POSTERS ON CLINICAL AND PRECLINICAL-STAGE CANDIDATES TO BE PRESENTED AT SITC, DEMONSTRATING THE STRENGTH OF IMMATICS' TCR-T PRAME FRANCHISE TO TARGET SOLID CANCERS

IMMATICS ANNOUNCES MULTIPLE PRESENTATIONS AT THE 39TH ANNUAL MEETING OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ON TCR-T THERAPY CANDIDATES TARGETING PRAME

DATA CONTINUES POSITIVE TREND AS ADDITIONAL PATIENTS ARE ENROLLED IN 3 COHORTS VACCINE WAS SAFE AND WELL TOLERATED BY PARTICIPANTS IN ALL 3 COHORTS PROTOCOL DEFINED IMMUNE RESPONSES WERE EXHIBITED IN OVER 70% OF PATIENTS A PHASE 2 STUDY EVALUATING THE VACCINE IN THE NEOADJUVANT SETTING IS PLANNED TO COMMENCE IN 2025 SAN JOSE, CALIF. , NOV. 8, 2024 /PRNEWSWIRE/ -- ANIXA BIOSCIENCES, INC. ("ANIXA" OR THE "COMPANY") (NASDAQ: ANIX), A BIOTECHNOLOGY COMPANY FOCUSED ON THE TREATMENT AND PREVENTION OF CANCER, TODAY ANNOUNCED A PRESENTATION OF NEW, UPDATED POSITIVE DATA FROM THE PHASE 1 CLINICAL TRIAL OF ITS BREAST CANCER VACCINE (NCT04674306) AT THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 39TH ANNUAL MEETING, BEING HELD IN HOUSTON, TEXAS.

ANIXA BIOSCIENCES AND CLEVELAND CLINIC PRESENT NEW UPDATED POSITIVE DATA FROM PHASE 1 STUDY OF BREAST CANCER VACCINE AT THE 39TH SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING

BOSTON, NOV. 08, 2024 (GLOBE NEWSWIRE) -- COMPASS THERAPEUTICS, INC. (NASDAQ: CMPX), A CLINICAL-STAGE, ONCOLOGY-FOCUSED BIOPHARMACEUTICAL COMPANY DEVELOPING PROPRIETARY ANTIBODY-BASED THERAPEUTICS, TODAY ANNOUNCED ITS POSTER PRESENTATION ENTITLED PHARMACODYNAMIC AND RESPONSE BIOMARKERS IN THE MONOTHERAPY ARM OF A PHASE 1 TRIAL OF CTX-471, A NOVEL ANTI-CD137 AGONIST ANTIBODY AT THE 39TH SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING, FROM NOVEMBER 6-10, 2024 IN HOUSTON, TX.

COMPASS THERAPEUTICS PRESENTS NOVEL BIOMARKER DATA RELATED TO CTX-471 CLINICAL ACTIVITY AT THE 39TH SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) ANNUAL MEETING

MDNA113 IS A NOVEL IL-13R2 TUMOR-TARGETED AND MASKED BISKIT (BIFUNCTIONAL SUPERKINE FOR IMMUNOTHERAPY), ENGINEERED TO DELIVER AN ANTI-PD1-IL-2 SUPERKINE (ANTI-PD1-IL-2 SK ) TO THE TUMOR MICROENVIRONMENT (TME), WHERE IT IS CONDITIONALLY ACTIVATED BY TUMOR-ASSOCIATED PROTEASES

MEDICENNA PRESENTS PRECLINICAL DATA FROM ITS ANTI-PD1-IL-2 BISKIT AND IL-2 SUPER AGONIST PROGRAMS AT THE 39TH ANNUAL MEETING OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC)

PHILADELPHIA AND VANCOUVER, BRITISH COLUMBIA, NOV. 08, 2024 (GLOBE NEWSWIRE) -- BRIACELL THERAPEUTICS CORP. (NASDAQ: BCTX, BCTXW) (TSX: BCT) (BRIACELL OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY THAT DEVELOPS NOVEL IMMUNOTHERAPIES TO TRANSFORM CANCER CARE, TODAY IS PLEASED TO REPORT PRECLINICAL DATA SHOWING STRONG ANTI-CANCER ACTIVITY OF ITS NEXT GENERATION, PERSONALIZED, OFF-THE-SHELF, CELL-BASED BREAST AND PROSTATE CANCER IMMUNOTHERAPIES, BRIA-BRES+ AND BRIA-PROS+, RESPECTIVELY, DURING A POSTER SESSION AT THE 2024 SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) 39TH ANNUAL MEETING, HELD NOVEMBER 6-10, 2024, IN HOUSTON, TX.

BRIACELL SHOWCASES ROBUST ANTI-CANCER ACTIVITY OF PERSONALIZED OFF-THE-SHELF IMMUNOTHERAPY PIPELINE AT THE 2024 SITC CONFERENCE

MARSEILLE, FRANCE--(BUSINESS WIRE)-- #ANKET--REGULATORY NEWS: INNATE PHARMA SA (EURONEXT PARIS: IPH; NASDAQ: IPHA) (INNATE OR THE COMPANY) TODAY ANNOUNCED THAT NEW PRECLINICAL DATA SUPPORTING THE CLINICAL DEVELOPMENT OF ITS PROPRIETARY NEXT GENERATION ANTIBODY-DRUG CONJUGATE (ADC) AND INNOVATIVE TETRA-SPECIFIC ANKET WILL BE PRESENTED AT THE SITC ANNUAL MEETING 2024. WE ARE THRILLED TO SHARE OUR LATEST PRECLINICAL DATA AT THE SITC ANNUAL MEETING, HIGHLIGHTING THE POTENTIAL OF IPH6501, OUR TETRA-SPE.

INNATE PHARMA HIGHLIGHTS DATA FROM ITS INNOVATIVE ONCOLOGY PORTFOLIO SELECTED FOR THE SITC ANNUAL MEETING 2024

HONG KONG , NOV. 7, 2024 /PRNEWSWIRE/ -- AT THE 2024 ANNUAL MEETING OF THE SOCIETY FORIMMUNOTHERAPY OF CANCER (SITC 2024), HELD IN HOUSTON, USA, FROM NOVEMBER 6 - 10, AKESO BIOPHARMA (9926. HK) PRESENTED THE MECHANISM OF ACTION (MOA) RESEARCH FINDINGS OF ITS INNOVATIVE BISPECIFIC ANTIBODY, AK132, TARGETING BOTH CLAUDIN18.2 (CLDN18.2) AND CD47.

AKESO PUBLISHED MECHANISM OF ACTION FOR CLDN18.2/CD47 BISPECIFIC ANTIBODY AK132 FOR THE FIRST TIME AT SITC ANNUAL MEETING

LESS FREQUENT IV DOSING WITH NEMVALEUKIN IN PATIENTS WITH SELECT ADVANCED SOLID TUMORS, INCLUDING OVARIAN CANCER AND MUCOSAL MELANOMA, SHOWED TUMOR SITE-SPECIFIC PHARMACODYNAMIC ACTIVITY AND IMMUNE ACTIVATION

SITE Centers

SITC

Price

Returns

Dividends

Yield

Dividends

No items found.

Financials Overview

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

Diversification by Country

Press Releases

Related News, Articles and Videos

Historical Scores

You might also be interested in

SITC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Returns

Dividends

Yield

Dividends

No items found.

Financials Overview

Financials Overview

Financial Reports

No items found.

Diversification by Property Type

Diversification by Country

Press Releases

Related News, Articles and Videos

Historical Scores

You might also be interested in

SITC